Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01513759 · ClinicalTrials.gov registry record · Phase 3
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT01513759 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 150 participants.
The verdict
NCT01513759, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right ventricle (RV) to left ventricle (LV) diameter within 48 =/- 6 hours in participants with massive or submassive PE.
Interventions
- DRUG recombinant tissue plasminogen activator
- DEVICE EKOS EkoSonic Endovascular System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2012-06-07 |
| Est. Completion | 2013-02-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01513759
The ClinicalTrials.gov registry entry for NCT01513759 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant tissue plasminogen activator is the first listed.
NCT01513759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01513759 about?
NCT01513759 is a clinical study titled "Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy". The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right ventricle (RV) to left ventricle (LV) diameter within 48 =/- 6 hours in parti...
What is the current status of trial NCT01513759?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2012-06-07. Estimated completion is 2013-02-17.
What interventions are being tested in trial NCT01513759?
The interventions under investigation include: recombinant tissue plasminogen activator (DRUG), EKOS EkoSonic Endovascular System (DEVICE).
Who is sponsoring clinical trial NCT01513759?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.